{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T04:49:11Z","timestamp":1773463751543,"version":"3.50.1"},"reference-count":19,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,3,14]]},"DOI":"10.1248\/bpb.b25-00800","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T22:11:54Z","timestamp":1773439914000},"page":"496-502","source":"Crossref","is-referenced-by-count":0,"title":["Bortezomib Induces Apoptosis &lt;i&gt;via&lt;\/i&gt; Upregulation of Abhd4 in Peripheral Nerve Cells"],"prefix":"10.1248","volume":"49","author":[{"given":"Yusuke","family":"Konishi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"},{"name":"Technology Innovation, Sysmex Corporation, 1\u20135\u20131 Wakinohama-Kaigandori, Chuo-ku, Kobe 651\u20132271, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Omura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ijichi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nishiguchi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryunosuke","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Education and Research Center for Clinical Pharmacy, Kobe Pharmaceutical University, 4\u201319\u20131 Motoyamakita-machi, Higashinada-ku, Kobe 658\u20138558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Kitahiro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Itohara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"},{"name":"Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1\u20131\u20131 Tsushima-naka, Kita-ku, Okayama 700\u20138558, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kobe University Hospital, 7\u20135\u20132 Kusunoki-cho, Chuo-ku, Kobe 650\u20130017, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade<sup>\u00ae<\/sup>: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. <i>Oncologist<\/i>, <b>8<\/b>, 508\u2013513 (2003).","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Mikhael JR, Dingli D, Roy V, <i>et al<\/i>. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. <i>Mayo Clin. Proc.<\/i>, <b>88<\/b>, 360\u2013376 (2013).","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Yamamoto S, Egashira N. Pathological mechanisms of bortezomib-induced peripheral neuropathy. <i>Int. J. Mol. Sci.<\/i>, <b>22<\/b>, 888 (2021).","DOI":"10.3390\/ijms22020888"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Meregalli C, Chiorazzi A, Carozzi VA, Canta A, Sala B, Colombo M, Oggioni N, Ceresa C, Foudah D, La Russa F, Miloso M, Nicolini G, Marmiroli P, Bennett DL, Cavaletti G. Evaluation of tubulin polymerization and chronic inhibition of proteasome as cytotoxicity mechanisms in bortezomib-induced peripheral neuropathy. <i>Cell Cycle<\/i>, <b>13<\/b>, 612\u2013621 (2014).","DOI":"10.4161\/cc.27476"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Trevisan G, Materazzi S, Fusi C, Altomare A, Aldini G, Lodovici M, Patacchini R, Geppetti P, Nassini R. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. <i>Cancer Res.<\/i>, <b>73<\/b>, 3120\u20133131 (2013).","DOI":"10.1158\/0008-5472.CAN-12-4370"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. <i>Cell Cycle<\/i>, <b>7<\/b>, 940\u2013949 (2008).","DOI":"10.4161\/cc.7.7.5625"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. <i>Exp. Neurol.<\/i>, <b>238<\/b>, 225\u2013234 (2012).","DOI":"10.1016\/j.expneurol.2012.08.023"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Moschetti G, Amodeo G, Maftei D, Lattanzi R, Procacci P, Sartori P, Balboni G, Onnis V, Conte V, Panerai A, Sacerdote P, Franchi S. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. <i>J. Neuroinflammation<\/i>, <b>16<\/b>, 89 (2019).","DOI":"10.1186\/s12974-019-1461-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Meregalli C, Marjanovic I, Scali C, Monza L, Spinoni N, Galliani C, Brivio R, Chiorazzi A, Ballarini E, Rodriguez-Menendez V, Carozzi VA, Alberti P, Fumagalli G, Pozzi E, Canta A, Quartu M, Briani C, Oggioni N, Marmiroli P, Cavaletti G. High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats. <i>J. Neuroinflammation<\/i>, <b>15<\/b>, 232 (2018).","DOI":"10.1186\/s12974-018-1270-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kortuem KM, Stewart AK. Carfilzomib. <i>Blood<\/i>, <b>121<\/b>, 893\u2013897 (2013).","DOI":"10.1182\/blood-2012-10-459883"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Malacrida A, Semperboni S, Di Domizio A, Palmioli A, Broggi L, Airoldi C, Meregalli C, Cavaletti G, Nicolini G. Tubulin binding potentially clears up bortezomib and carfilzomib differential neurotoxic effect. <i>Sci. Rep.<\/i>, <b>11<\/b>, 10523 (2021).","DOI":"10.1038\/s41598-021-89856-3"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Haberberger RV, Barry C, Matusica D. Immortalized dorsal root ganglion neuron cell lines. <i>Front. Cell. Neurosci.<\/i>, <b>14<\/b>, 184 (2020).","DOI":"10.3389\/fncel.2020.00184"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Nishiguchi H, Omura T, Sato A, Kitahiro Y, Yamamoto K, Kunimasa J, Yano I. Luteolin protects against 6-hydroxydopamine-induced cell death <i>via<\/i> an upregulation of HRD1 and SEL1L. <i>Neurochem. Res.<\/i>, <b>49<\/b>, 117\u2013128 (2024).","DOI":"10.1007\/s11064-023-04019-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPAR\u03b1 agonist palmitoylethanolamide. <i>Br. J. Pharmacol.<\/i>, <b>168<\/b>, 1430\u20131444 (2013).","DOI":"10.1111\/bph.12029"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Pastori V, D\u2019Aloia A, Blasa S, Lecchi M. Serum-deprived differentiated neuroblastoma F-11 cells express functional dorsal root ganglion neuron properties. <i>PeerJ<\/i>, <b>7<\/b>, e7951 (2019).","DOI":"10.7717\/peerj.7951"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha\/beta-hydrolase 4 in this pathway. <i>J. Biol. Chem.<\/i>, <b>281<\/b>, 26465\u201326472 (2006).","DOI":"10.1074\/jbc.M604660200"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Simpson CD, Hurren R, Kasimer D, MacLean N, Eberhard Y, Ketela T, Moffat J, Schimmer AD. A genome wide shRNA screen identifies \u03b1\/\u03b2 hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance. <i>Apoptosis<\/i>, <b>17<\/b>, 666\u2013678 (2012).","DOI":"10.1007\/s10495-012-0723-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Pero ME, Meregalli C, Qu X, Shin GJ, Kumar A, Shorey M, Rolls MM, Tanji K, Brannagan TH, Alberti P, Fumagalli G, Monza L, Grueber WB, Cavaletti G, Bartolini F. Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>118<\/b>, e2012685118 (2021).","DOI":"10.1073\/pnas.2012685118"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. <i>Cell Death Differ.<\/i>, <b>5<\/b>, 551\u2013562 (1998).","DOI":"10.1038\/sj.cdd.4400404"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/3\/49_b25-00800\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:50:09Z","timestamp":1773460209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/3\/49_b25-00800\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00800","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"article-number":"b25-00800"}}